Altered amyloid-β structure markedly reduces gliosis in the brain of mice harboring the Uppsala APP deletion

Autor: María Pagnon de la Vega, Stina Syvänen, Vilmantas Giedraitis, Monique Hooley, Evangelos Konstantinidis, Silvio R. Meier, Johanna Rokka, Jonas Eriksson, Ximena Aguilar, Tara L. Spires-Jones, Lars Lannfelt, Lars N. G. Nilsson, Anna Erlandsson, Greta Hultqvist, Martin Ingelsson, Dag Sehlin
Jazyk: angličtina
Rok vydání: 2024
Předmět:
Zdroj: Acta Neuropathologica Communications, Vol 12, Iss 1, Pp 1-16 (2024)
Druh dokumentu: article
ISSN: 2051-5960
DOI: 10.1186/s40478-024-01734-x
Popis: Abstract Deposition of amyloid beta (Aβ) into plaques is a major hallmark of Alzheimer’s disease (AD). Different amyloid precursor protein (APP) mutations cause early-onset AD by altering the production or aggregation properties of Aβ. We recently identified the Uppsala APP mutation (APPUpp), which causes Aβ pathology by a triple mechanism: increased β-secretase and altered α-secretase APP cleavage, leading to increased formation of a unique Aβ conformer that rapidly aggregates and deposits in the brain. The aim of this study was to further explore the effects of APPUpp in a transgenic mouse model (tg-UppSwe), expressing human APP with the APPUpp mutation together with the APPSwe mutation. Aβ pathology was studied in tg-UppSwe brains at different ages, using ELISA and immunohistochemistry. In vivo PET imaging with three different PET radioligands was conducted in aged tg-UppSwe mice and two other mouse models; tg-ArcSwe and tg-Swe. Finally, glial responses to Aβ pathology were studied in cell culture models and mouse brain tissue, using ELISA and immunohistochemistry. Tg-UppSwe mice displayed increased β-secretase cleavage and suppressed α-secretase cleavage, resulting in AβUpp42 dominated diffuse plaque pathology appearing from the age of 5–6 months. The γ-secretase cleavage was not affected. Contrary to tg-ArcSwe and tg-Swe mice, tg-UppSwe mice were [11C]PiB-PET negative. Antibody-based PET with the 3D6 ligand visualized Aβ pathology in all models, whereas the Aβ protofibril selective mAb158 ligand did not give any signals in tg-UppSwe mice. Moreover, unlike the other two models, tg-UppSwe mice displayed a very faint glial response to the Aβ pathology. The tg-UppSwe mouse model thus recapitulates several pathological features of the Uppsala APP mutation carriers. The presumed unique structural features of AβUpp42 aggregates were found to affect their interaction with anti-Aβ antibodies and profoundly modify the Aβ-mediated glial response, which may be important aspects to consider for further development of AD therapies.
Databáze: Directory of Open Access Journals
Nepřihlášeným uživatelům se plný text nezobrazuje